GLPwatch
Papers (10409)
Page 119 of 174, ranked by citation count.
- Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management.
- Pancreatic safety in Japanese patients with type 2 diabetes treated with once weekly dulaglutide 0.75 mg up to 52 weeks in phase 3 clinical trials.
- Exenatide induced acute kidney injury.
- GLP-1 Analog Alleviated Cognitive Dysfunction in Aged Rats Anaesthetized with Sevoflurane.
- Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report.
- Current updates on pharmacological roles of glucagon-like peptide 1 in obesity.
- Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes.
- Patient-reported outcomes of glucagon-like peptide-1 agonists on hidradenitis suppurativa severity.
- The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?
- Semaglutide and obesity: beyond the nutritional and lifestyle intervention?
- Liraglutide vs. sitagliptin add-on to metformin treatment for type 2 diabetes mellitus: Short-term cost-per-controlled patient in Italy.
- Preconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment.
- [Protective effects of glucagon-like peptide-1 on beta-cells: preclinical and clinical data].
- Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes.
- GLP-1RA versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: An updated meta-analysis of randomized controlled trials.
- New developments in GLP-1 agonist therapy for gestational diabetes: Systematic review on liraglutide, semaglutide, and exenatide from ClinicalTrials.gov.
- Rebound or Retention: A Meta-Analysis of Weight Regain After the Discontinuation of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Other Anti-obesity Drugs.
- Incretin-based Agents and Metabolic Dysfunction-associated Steatotic Liver Disease.
- GLP-1 and amylin receptor multiagonism with amycretin for obesity management.
- Should family physicians prescribe medication for obesity? YES.
- Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study.
- Risk of biliary diseases in patients with type 2 diabetes or obesity treated with tirzepatide: A meta-analysis.
- The Effect of Feeding Behavior on Hypothalamus in Obese Type 2 Diabetic Rats with Glucagon-like Peptide-1 Receptor Agonist Intervention.
- IDegLira Improves Metabolic Control in Patients with Type 2 Diabetes Previously Treated with Premix Insulin.
- Case Report of Acute Pancreatitis Associated With Combination Treatment of Dulaglutide and Glipizide.
- Insulin Glargine is More Suitable Than Exenatide in Preventing Muscle Loss in Non-Obese Type 2 Diabetic Patients with NAFLD.
- A case of insulin allergy successfully managed using multihexamer-forming insulin degludec combined with liraglutide.
- Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight.
- Effect of Swallow Balloon Therapy with the Combination of Semaglutide Oral Formulation: a Randomised Double-Blind Single-Centre Study.
- Nutrient-Stimulating Hormone-Based Therapies for Obesity.
- Superior Cerebrovascular Outcomes with Tirzepatide versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients.
- Clinical Efficacy of Once-weekly Glucagonlike Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes.
- Improving management of diabetic kidney disease: will GLP-1 receptor agonists have a role?
- Use of glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension : a systematic review.
- Efficacy of liraglutide added to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post-hoc analysis of LIRA-ADD2SGLT2i.
- Efficacy and safety of dulaglutide in patients with absolute insulin deficiency.
- Total and H-specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration.
- GLP-1 receptor agonists and alcohol use disorder: a systematic review.
- No effects of a 6-week intervention with a glucagon-like peptide-1 receptor agonist on pancreatic volume and oedema in obese men without diabetes.
- Newer Glucagon-Like Peptide-1 Receptor Agonists Are Associated With Improved Glycemic Control in US Adults With Type 2 Diabetes: A Population-Level Time Series Analysis.
- Nutrition Strategies for Next-Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence.
- [The new antidiabetic agents in the firing line.... safety reasons or witch hunt?].
- Conjugation to a cell-penetrating peptide drives the tumour accumulation of the GLP1R antagonist exendin(9-39).
- Incretin mimetics for weight loss forgive nonadherence.
- Effect of incretin-based therapies on blood pressure: a systematic review and meta-analysis.
- Effects of exenatide and liraglutide on postchallenge glucose disposal in individuals with normal glucose tolerance.
- Can Semaglutide offer hope for patients with obesity-related heart failure?
- Osteoprotegerin, Osteopontin, and Osteocalcin Are Associated With Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.
- Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting.
- Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 European Society of Cardiology Conference.
- Relative efficacy of GLP-1 and GLP-1/GIP receptor agonists in the prevention of alcohol-use disorders using a target trial emulation approach.
- Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.
- Multiple drug combination of anti-diabetic agents as a predictor for poor clinical response to liraglutide.
- GLP-1R/NPY2R regulate gene expression, ovarian and adrenal morphology in HFD mice.
- Cost-effectiveness analysis of four glucagon-like peptide-1 or glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists for the treatment of adult patients with overweight and obesity in China.
- Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multicenter Study.
- Therapy for NASH.
- Exenatide enhances INS-1 rat pancreatic β‑cell mass by increasing the protein levels of adiponectin and reducing the levels of C-reactive protein.
- Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies.
- A Systematic Review Identifying Critical Evidence Gaps in Reporting Dietary Change in Randomized Controlled Trials Prescribing Liraglutide, Semaglutide, or Tirzepatide.